Table 3

Crude RORs for specific infections

URTILRTIUTIOther infections
DrugNROR (95% CI)NROR (95% CI)NROR (95% CI)NROR (95% CI)
Biguanides38Reference65Reference30Reference166Reference
SU derivatives351.2 (0.8–1.9)581.2 (0.8–1.7)351.5 (0.9–2.5)1411.1 (0.9–1.4)
TZDs2332.3 (1.7–3.3)2321.4 (1.0–1.8)1131.4 (1.0–2.1)3670.8 (0.7–1.0)
DPP-4 I17112.3 (8.6–17.5)200.8 (0.5–1.4)131.2 (0.6–2.3)510.8 (0.6–1.2)
Insulins2151.5 (1.1–2.2)4251.8 (1.4–2.3)1861.7 (1.1–2.5)1,0151.7 (1.4–2.0)
OAD + OAD331.6 (1.0–2.5)330.9 (0.6–1.4)291.7 (1.0–2.9)650.7 (0.5–0.9)
OAD + insulin41.1 (0.4–3.1)81.3 (0.6–2.7)103.5 (1.7–7.2)271.7 (1.1–2.6)
≥3 ADs132.5 (1.3–4.7)80.9 (0.4–1.9)61.5 (0.6–3.6)160.7 (0.4–1.2)
  • ADs, antidiabetic drugs; DPP-4 I, dipeptidyl peptidase inhibitors; OAD, oral antidiabetic drug; SU, sulfonylurea; TZDs, thiazolidinediones.